|
gptkbp:instanceOf
|
gptkb:protein
cytokine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L03AB07
|
|
gptkbp:CASNumber
|
9008-11-1
|
|
gptkbp:contraindication
|
hypersensitivity to interferon beta
|
|
gptkbp:discoveredIn
|
1970s
|
|
gptkbp:encodedBy
|
gptkb:IFNB1_gene
|
|
gptkbp:foundIn
|
mammals
|
|
gptkbp:halfLife
|
5-10 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon beta
|
|
gptkbp:inducedBy
|
expression of antiviral proteins
|
|
gptkbp:inhibitedBy
|
viral replication
|
|
gptkbp:marketedAs
|
gptkb:Rebif
gptkb:Betaseron
gptkb:Avonex
gptkb:Extavia
|
|
gptkbp:mechanismOfAction
|
modulates immune response
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
human cells
|
|
gptkbp:regulates
|
immune system
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
|
|
gptkbp:sideEffect
|
injection site reaction
flu-like symptoms
|
|
gptkbp:subspecies
|
gptkb:interferon_beta-1b
gptkb:interferon_beta-1a
|
|
gptkbp:UNII
|
PIF9Y50F41
|
|
gptkbp:usedFor
|
multiple sclerosis treatment
|
|
gptkbp:bfsParent
|
gptkb:Plegridy
|
|
gptkbp:bfsLayer
|
6
|